Home UVB therapy for psoriasis as effective and safe as hospital treatmentMay 08, 2009Research: Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: Pragmatic multicenter randomized controlled non-inferiority trial For patients with psoriasis, treatment with ultraviolet B (UVB) at home is as effective and as safe as conventional hospital based phototherapy, concludes a study published on bmj.com today. Patients also find home UVB therapy less of a burden and are more satisfied with treatment, the findings show. Psoriasis is a common, chronic inflammatory skin condition that causes significant disability to sufferers and their families. UVB treatment is safe and effective, but few patients in the UK ever receive it because of limited availability and time constraints (a course of treatment typically involves attending hospital three times each week for eight to 10 weeks). Furthermore, most dermatologists believe that home phototherapy is inferior to hospital treatment and that it carries more risks, despite there being no evidence to support this. So a team of researchers in the Netherlands compared the safety and effectiveness of home phototherapy with standard hospital based phototherapy. They identified 196 patients with psoriasis from 14 hospital dermatology departments. Patients were randomised to receive either home UVB phototherapy or hospital based phototherapy. The home group used a phototherapy unit in their homes, while the hospital group received the treatment at their local hospital. Both treatment at home and at the hospital were applied according to standard routine practice. Disease severity after treatment was measured using recognised scoring scales. Side effects and total cumulative dose of UVB were also recorded. Both groups completed questionnaires to assess the burden of treatment, quality of life and patient satisfaction for the two treatment settings. The results show that home phototherapy is equally safe and equally effective as outpatient phototherapy, both clinically and in terms of quality of life. Patients treated at home reported a significantly lower burden of treatment and greater satisfaction with treatment. And the majority of patients said they would prefer home UVB therapy over hospital based therapy in the future. This study clearly shows that home UVB phototherapy is a good alternative that should be considered instead of the standard outpatient UVB phototherapy for patients with psoriasis, say the authors. They suggest that current guidelines should be updated to reflect this. This study highlights an important gap in the provision of treatment for patients with psoriasis and it is timely to reassess conventional treatments such as UVB, writes Professor Alex Anstey from the Royal Gwent Hospital, in an accompanying editorial. To make home based phototherapy become a reality, an economic assessment of different UVB service models is needed, he says. Meanwhile, healthcare commissioners should work with local dermatologists to improve access to UVB phototherapy services. Experience in Germany, the US, the Netherlands, and Scotland confirms that it would be feasible and practical to implement home based UVB phototherapy, he concludes. BMJ-British Medical Journal |
|||||||||||||||||||||
| Related Phototherapy Current Events and Phototherapy News Articles Universal screening lowers risk of severe jaundice in infants Screening all newborns for excessive bilirubin in the blood can significantly decrease the incidence of severe jaundice which, in extreme cases, can lead to seizures and brain damage. Baby boomers' boon? LED light and green tea cream to smooth facial wrinkles Scientists in Germany are reporting a major improvement in their potential new treatment for facial wrinkles that could emerge as an alternative to Botox and cosmetic surgery. Researchers find aggressive phototherapy can improve neurodevelopmental outcomes in some preemies Researchers at The University of Texas Medical School at Houston say the use of aggressive phototherapy reduces the odds that tiny premature infants will develop neurodevelopmental impairment such as cerebral palsy, blindness, deafness or physical or mental challenges. Health risks, benefits come with delayed umbilical cord clamping Waiting just a few minutes to clamp the umbilical cord after a baby is born could boost iron stores in the newborn's blood, but delayed cord clamping comes with an increased risk of jaundice, according to a new review of studies. New findings show Enbrel significantly reduced levels of C-reactive protein Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Simple test accurately predicts risk of serious jaundice in newborns A simple test can accurately identify which newborn babies are at risk for developing dangerous levels of jaundice, according to researchers at The Children's Hospital of Philadelphia. FSU chemists using light-activated molecules to kill cancer cells A key challenge facing doctors as they treat patients suffering from cancer or other diseases resulting from genetic mutations is that the drugs at their disposal often don't discriminate between healthy cells and dangerous ones -- think of the brute-force approach of chemotherapy, for instance. Networking around the clock A Brandeis University study published in Cell this week shows for the first time experimentally that the circadian cells in fruit flies function as a network that enables the insects to adapt their behavior according to seasonal changes. New analyses reinforce efficacy of Remicade in treatment of severe psoriasis Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving REMICADE® (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis Area Severity Index (PASI 75). Remicade therapy shown to improve productivity in patients treated for chronic plaque psoriasis Investigators reported today at the American Academy of Dermatology annual meeting that patients with moderate to severe plaque psoriasis receiving REMICADE® (infliximab) induction and maintenance therapy experienced significant improvements in productivity at week 10, which were sustained through week 50. More Phototherapy Current Events and Phototherapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||